White Paper: Orphan Drugs in Germany - lessons learned from AMNOG

Mon, 2018 / 10 / 01

The AMNOG, the legislative framework governing the market access of innovative prescription drugs in Germany, has implicated a paradigm shift in the examination of the value of a pharmaceutical and in the setting of an appropriate reimbursement level for the product. Based on the evidence of available study data, the additional benefit over the existing standard of care is assessed by the most powerful German health authority, the G-BA. Depending on the classification of the benefit category, the pharmaceutical manufacturer negotiates the final refunded price with the umbrella organization of the German statutory health insurances.

For orphan drugs, there are specific challenges that the manufacturer has to meet. Due to the randomness of the disease, subpopulations are small and study data are scarce. This leads to a considerable uncertainty about the perceived value of the drug and, thus, to intense and sometimes tough negotiations with high rebates in the end. Pharmaceutical companies planning to introduce new orphan drugs into the German market should prepare well in advance a sound and stringent strategy to optimize the performance throughout the entire market access processes.

Tim Kirchmann, Heike Kielhorn-Schönermark and Prof. Matthias P. Schönermark M.D., Ph. D. wrote the white paper „Orphan Drugs in Germany – lessons learned from AMNOG, best and worst practices and strategic implications” that elaborates all relevant orphan drug issues and describes important recommendations for manufacturers facing these challenges.

Exclusive download white paper

We would be pleased to provide you with the white paper free of charge. Please send us your contact details using the form provided.

Orphan drugs in Germany

Lessons learned from AMNOG, best and worst practices and strategic implications

go to form